(C) 2011 American

Institute of Physics. [doi: 10.1063/1.3569835]“
“Purpose: A new protocol for ABO-incompatible (ABO-i) kidney transplantation including rituximab was introduced in January 2005 in our institute. This study reviewed the results and evaluated the use of low-dose rituximab in ABO-i kidney transplantation.

Material and methods: Seventy-four de novo ABO-i kidney transplantations were performed at Tokyo Women’s Medical University between January 2005 and August 2010. The immunosuppressive protocol was consisting of tacrolimus, mycophenolate mofetil, and methylprednisolone. All the patients received induction therapy with basiliximab. The pre-conditioning protocol included double-filtration plasmapheresis and a single dose of rituximab. A dose of 500 mg/ body rituximab https://www.selleckchem.com/products/Adriamycin.html was initially employed and yielded excellent results (Group I, n = 24). Afterward, the dose of rituximab was reduced to 200 mg/ CA4P body in January 2007 (Group II, n = 50).

Results: Seventy-four de novo ABO-i recipients were treated with this protocol, and all patients underwent kidney transplantation

successfully. Effective elimination of the peripheral blood CD19 cells was observed in both groups. However, the peripheral blood CD19 levels were still low in both groups at 24 months after treatment.

Conclusion: The patients in Group II showed excellent results similar to Group I. These results suggest that the low dose of rituximab (200 mg/ body) is the sufficient dose in ABO-i kidney transplantation.”
“PURPOSE: To evaluate whether intracameral triamcinolone has an effect on anterior segment MDV3100 inflammation and visual axis obscuration after pediatric cataract surgery with intraocular (IOL) implantation

SETTING: Haim Cataract and IOL Research Institute; Ahmedabad, India.

METHODS: This retrospective age-matched case-control study comprised consecutive eyes of children having phacoaspiration; posterior capsulectomy, vitrectomy, and IOL implantation.

In the study group, eyes received a standardized application of an intracameral preservative-free triamcinolone acetonide suspension intraoperatively. In the control group, age-matched consecutive eyes had surgery with a similar technique but without intracameral preservative-free triamcinolone acetonide Cell deposits, posterior synechias. visual axis obscuration, and intraocular pressure (IOP) were evaluated 1 month and 12 months postoperatively.

RESULTS: The mean patient age at surgery was 9 15 months +/- 5.04 (SD) in the study group (41 eyes) and 9.34 +/- 5.10 months in the control group (83 eyes) (P = .91). The visual axis was not obscured in any eye in the study group, while 9 eyes (10.8%) in the control group had an obscured axis, the difference between groups was statistically significant (P<.029) Six eyes (7.2%) in the control group required secondary membranectomy with pars plana vitrectomy.